Skip to content
Riskpilot
← Back to search
Sign in
Get full access
CALLUNA PHARMA AS
AS
Active
Org 932255189
Gaustadalléen 21, 0349
Oslo
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2023 · 2 years old
10 employees
Monitor
Share
Norway
/
Companies
/
Research and experimental development on natural sciences and engineering
/
CALLUNA PHARMA AS
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
NOK millions
0M
8M
16M
23M
31M
27M
2024
EBITDA
NOK millions
0M
-8M
-17M
-25M
-34M
-27M
2024
Income statement
NOK thousands
Item
2024
Revenue
26 905
Staff expenses
−32 017
EBITDA
−26 638
Depreciation & amort.
−0
EBIT
−26 638
Net financials
14 727
Profit before tax
−11 911
Tax
−0
Net profit
−11 911
Balance sheet
NOK thousands
Item
2024
Total assets
853 584
Equity
769 267
Long-term debt
0
Short-term debt
84 317
Total debt
84 317
Financial ratios
5-year trend
EBITDA margin
-99.0%
This company
15.8%
Market median
-727% vs market
2024
2024
Equity ratio
90.1%
This company
38.2%
Market median
+136% vs market
2024
2024
Return on equity
-1.5%
This company
18.4%
Market median
-108% vs market
2024
2024
Net profit margin
-44.3%
This company
8.1%
Market median
-647% vs market
2024
2024
Asset turnover
0.03×
This company
1.12×
Market median
-97% vs market
2024
2024
Debt / equity
0.11×
This company
0.62×
Market median
+82% vs market
2024
2024
Annual reports & filings
Annual report 2024
Filed via Brønnøysundsregistrene · Period 2023-09-01 – 2024-12-31
View
PDF
More on CALLUNA PHARMA AS
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
